Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07689006 · ClinicalTrials.gov registry record
Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 341
- Enrollment target
NCT07689006: Completed study, sponsored by Bristol-Myers Squibb.
NCT07689006 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 341 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07689006 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 341 participants
- Enrollment target
Study Summary
This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after prior exposure to lenalidomide and a proteasome inhibitor.
Interventions
- DRUG Pomalidomide-containing regimens
- DRUG Non-pomalidomide-containing regimens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2024-12-23 |
| Est. Completion | 2025-03-28 |
What the finished NCT07689006 record still lists
NCT07689006 is an observational study that tracks outcomes without assigning an intervention. The registered 341 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Pomalidomide-containing regimens is the first listed.
NCT07689006 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07689006 about?
NCT07689006 is a clinical study titled "Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens". This retrospective observational study will use data from the OneOncology United States database to evaluate clinical outcomes in adults with relapsed/refractory multiple myeloma who received pomalidomide-containing or non-pomalidomide-containing treatment as second-line or third-line therapy after ...
What is the current status of trial NCT07689006?
This trial is currently completed. The enrollment target is 341 participants. The study started on 2024-12-23. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT07689006?
The interventions under investigation include: Pomalidomide-containing regimens (DRUG), Non-pomalidomide-containing regimens (DRUG).
Who is sponsoring clinical trial NCT07689006?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06852170 · 341 participants · NA
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI